M&A Deal Summary |
|
---|---|
Date | 2020-06-10 |
Target | LG Chem - LCD Polarizer Business |
Sector | Chemicals |
Buyer(s) | Ningbo Shanshan |
Sellers(s) | LG Chem |
Deal Type | Divestiture |
Deal Value | 1.1B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1992 |
Sector | Chemicals |
Employees | 8,095 |
Revenue | 19.1B CNY (2023) |
Ningbo Shanshan is an entity that provides apparel and lithium battery materials. The company provides lithium battery cathode materials, lithium battery anode material products, silicon-based anode materials, and electrolyte products. It is also involved in energy management services, such as new energy business activities, such as the construction of charging piles, operation of new energy vehicles, and energy management services. It engages in the financial leasing and venture capital businesses. Ningbo Shanshan was founded in 1992 and is based in Ningbo, China.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Chemicals) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (China) | 1 of 1 |
Year (2020) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
LG Chem engaged in manufacture of petrochemicals like polyvinyl chloride (PVC) resins, low-density polyethylene (LDPE), poly styrene (PS), acrylonitrile butadiene styrene (ABS), bisphenol. LG Chem was founded in 1947 and is based in Seoul, South Korea.
DEAL STATS | # |
---|---|
Overall | 2 of 3 |
Sector (Chemicals) | 2 of 2 |
Type (Divestiture) | 2 of 3 |
Country (China) | 1 of 1 |
Year (2020) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-05-12 |
LG NanoH2O
El Segundo, California, United States LG NanoH2O, Inc. designs, develops, manufactures and markets reverse osmosis (RO) membranes that lower the cost of desalination. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2023-01-19 |
Aveo Oncology
Boston, Massachusetts, United States Aveo Oncology is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. Aveo Oncology's product candidates are targeted against important mechanisms known or believed to be involved in cancer. Aveo Oncology was founded in 2001 and is based in Boston, Massachusetts. |
Buy | $571M |